<?xml version="1.0" encoding="UTF-8"?>
<p id="Par12">Our main outcome was either the first introduction of aRMM(s) for medicines without aRMMs at the time of authorisation or the first discontinuation of at least one of the aRMMs for medicines with aRMMs at the time of authorisation.</p>
